Jeito
Emilie Desfontaine has more than 10 years of experience in global drug development strategy, including strong expertise in rare diseases and 10 years of experience at the European Medicines Agency, first as coordinator and then as scientific pediatric lead, including interactions with the FDA.
Emilie holds an MBA from Imperial College Business School in London.
Jeito
Jeito is a next-generation fund with a patient benefit driven approach, that focuses both on financing ground-breaking medical innovation and promoting positive societal impact.